美国芝加哥当地时间6月2日-6日即将迎来在2023年度的全球规模最大的肿瘤领域学术交流盛会——第59届美国临床肿瘤学会（ASCO）会议。届时，全球顶尖肿瘤学专家将汇聚一堂，共同分享、探讨国际最前沿的临床肿瘤学研究成果和治疗技术。
目前，ASCO官网已公布了本次会议的日程和摘要题目。本期【血液肿瘤资讯】整理了2023 ASCO年会全体大会及口头报告（Oral Abstract Session）专场的恶性血液肿瘤重磅研究，与读者分享。
全体大会
专场时间：2023年6月5日，星期一，上午2:00 – 上午5:00（以下时间均为中国时间）
专场主席：Katia Khoury，Kevin Kalinsky
摘要号：LBA4
SWOG S1826：一项纳武利尤单抗（N） - AVD vs 维布妥昔单抗（BV）- AVD治疗晚期（AS）经典霍奇金淋巴瘤（HL）的随机研究
SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).
讲者：Alex Francisco Herrera, MD | City of Hope National Medical Center
口头报告专场：恶性血液肿瘤——白血病、骨髓增生异常综合征和同种异体移植
专场时间：2023年6月3日，星期六，上午02:00 – 上午05:00
专场主席：Andrew Artz | City of Hope National Medical Center；Vanessa Kennedy | University of California, San Francisco
摘要号：7000
obecabtagene autoleucel [obe-cel，AUTO1, 一种具有较快解离速度的嵌合抗原受体（CAR）]治疗复发/难治性（R/R）成人急性B淋巴细胞白血病（B - ALL）的疗效及安全性：关键FELIX研究的主要结果
Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.
讲者：Claire Roddie, PhD, FRCPath, MBChB, MRCP, BSc | University College London
摘要号：7001
作为R/R B - ALL的美国食品药品监督管理局（FDA）获批疗法，brexucabtagene autoleucel治疗R / R B - ALL成人患者的结局
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.
讲者：Gregory Roloff, MD | University of Chicago
摘要号：7002
经酪氨酸激酶抑制剂（TKI）制备的CD5 CAR - T细胞治疗R / R 急性T淋巴细胞白血病（T - ALL）患者的抗肿瘤活性增强
Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL.
讲者：LaQuisa C Hill, MD | Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital
摘要号：7003
COMMANDS试验的疗效及安全性结果：一项评估luspaterceept vs重组人红细胞生成素（ESA）治疗伴低风险骨髓增生异常综合征（LR - MDS）的促红细胞生成剂初次输血依赖（TD）患者的3期研究
Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)‑naive transfusion-dependent (TD) patients (pts) with lower‑risk myelodysplastic syndromes (LR-MDS).
讲者：Guillermo Garcia-Manero, MD | Department of Leukemia, University of Texas M.D. Anderson Cancer Center
摘要号：7004
IMerge：imetelstat治疗伴低风险骨髓增生异常综合征（LR - MDS）的严重输血依赖（TD）非del（5q）且对重组人红细胞生成素（ESA）复发/难治（R / R）患者的一项随机、双盲、安慰剂对照的3期研究结果
IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).
讲者：Amer Methqal Zeidan, MBBS | Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University
摘要号：7005
CD123 NK细胞接合物SAR443579治疗R / R急性髓性白血病（AML）、急性B淋巴细胞白血病或高危骨髓异常增生的首次人体研究
A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
讲者：Anthony Selwyn Stein, MD | City of Hope National Medical Center
摘要号：7006
Alliance A041703：inotuzumab ozogamicin联合blinatumumab的去化疗方案治疗新诊断、Ph阴性、CD22阳性老年急性B淋巴细胞白血病患者
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.
讲者：Matthew Joseph Wieduwilt, MD, PhD | Atrium Health Wake Forest Baptist Comprehensive Cancer Center
摘要号：7007
剂量调整的EPOCH联合inotuzumab ozogamicin （InO）治疗R / R B淋巴母细胞白血病/淋巴瘤（B - ALL）成人患者的I期临床试验
A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).
讲者：Noam Edward Kopmar, MD | University of Washington/Fred Hutchinson Cancer Center
摘要号：7008
AYA ALL的特殊癌症治疗和生存：一项美国多州分析
Specialty cancer care and survival in AYA ALL: A U.S. multi-state analysis.
讲者：Lori S. Muffly, MD, MS | Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine
口头报告专场：恶性血液肿瘤——恶性浆细胞疾病
专场时间：2023年6月4日，星期日，上午02:15 – 上午5:15
专场主席：Amandeep Godara | Huntsman Cancer Institute；Luciano Costa | University of Alabama at Birmingham
摘要号：8000
卡非佐米、来那度胺和地塞米松（KRd） vs. elotuzumab和KRd治疗符合移植条件的新诊断多发性骨髓瘤（MM）患者：一项开放标签、随机、3期研究的诱导后应答和MRD结果
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.
讲者：Stefan Knop, MD | Wuerzburg University Medical Center
摘要号：8001
卡非佐米、泊马度胺和地塞米松（KPd）维持治疗高危骨髓瘤患者：一项2期研究的安全性导入期
Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in.
讲者：Ajay K. Nooka, MBBS | Winship Cancer Center of Emory University
摘要号：8002
Teclistamab （tec）和talquetamab （tal）（同时靶向于BCMA和GPRC5D）治疗复发/难治性多发性骨髓瘤（RRMM）患者的RedirecTT-1研究的首次结果
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
讲者：Yael C Cohen, MD | Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University
摘要号：8003
Talquetamab（tal）联合达雷妥尤单抗（dara）治疗复发/难治性多发性骨髓瘤（RRMM）患者： TRIMM-2研究的最新结果
Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.
讲者：Bhagirathbhai R. Dholaria, MBBS | Vanderbilt University Medical Cente
摘要号：8004
PHE885（一种T-Charge制备的靶向BCMA的CAR-T细胞疗法）治疗RRMM患者的最新I期研究结果
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).
讲者：Adam Samuel Sperling, MD, PhD | Dana-Farber Cancer Institute
摘要号：8005
BCMA/CD19双靶向fast CAR-T GC012F治疗复发/难治性多发性骨髓瘤（RRMM）患者的开放标签I期研究的更新结果
Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).
讲者：杜鹃教授 | 上海长征医院
摘要号：8006
LINKER-MM1研究：Linvoseltamab（REGN5458）治疗复发/难治性多发性骨髓瘤（RRMM）患者
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
讲者：Hans C. Lee, MD | The University of Texas MD Anderson Cancer Center
摘要号：8007
评估belantamab mafodotin（belamaf）单药 vs 泊马度胺联合低剂量地塞米松（Pd）治疗复发/难治性多发性骨髓瘤（RRMM）患者的疗效与安全性的一项3期、开放标签、随机研究：DREAMM‑3
A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM‑3.
讲者：Katja Weisel, MD | University Medical Center of Hamburg-Eppendorf
摘要号：8008
Elranatamab治疗既往经B细胞成熟抗原（BCMA）靶向治疗的复发/难治性多发性骨髓瘤（RRMM）患者的疗效和安全性：来自MagnetisMM研究的汇总分析
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
讲者：Ajay K. Nooka, MBBS | Winship Cancer Institute, Emory University Hospital
口头报告专场：恶性血液肿瘤——淋巴瘤和慢性淋巴细胞白血病
专场时间：2023年6月6日，星期二，下午10:45 – 上午13:45
专场主席：Boyu Hu | Hunstman Cancer Institute at the University of Uta；Jakub Svoboda | University of Pennsylvania
摘要号：7500
一项IVO vs IO治疗既往未接受治疗的老年慢性淋巴细胞白血病（CLL）患者的3期研究结果以及COVID-19的影响（Alliance）
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).
讲者：Jennifer Ann Woyach, MD | The Ohio State University Comprehensive Cancer Center
摘要号：7501
Lisocabtagene maraleucel（liso - cell）治疗R/R慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）: TRANSCEND CLL 004研究的初步分析
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.
讲者：Tanya Siddiqi, MD | City of Hope National Medical Center
摘要号：7502
MOLTO研究的结果：评估维奈克拉、阿替利珠单抗联合obinutuzumab治疗Richter综合征疗效的一项多中心、开放标签、II期临床试验
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.
讲者：Anna Maria Frustaci, MD | Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda
摘要号：7503
Golidocitinib治疗难治性或复发性外周T细胞淋巴瘤：国际关键性研究结果的主要分析（JACKPOT8）
Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).
讲者：中国广东，中山大学附属肿瘤防治中心，蔡清清教授
摘要号：7504
CHOP联合抗CCR4抗体mogamulizumab治疗老年CCR4阳性成人T细胞白血病/淋巴瘤患者的2期临床试验
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma.
讲者：Ilseung Choi | Department of Hematology and Cell therapy, National Hospital Organization Kyushu Cancer Center
摘要号：7505
观察 vs 放疗用于对于标准免疫化疗完全缓解的原发性纵隔B细胞淋巴瘤患者：IELSG37随机试验
Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.
讲者：Emanuele Zucca, MD | Institute of Oncology Research; Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Science, Universita’ della Svizzera italiana; International Extranodal Lymphoma Study Group (IELSG)
摘要号：7506
Epcoritamab 联合R2方案治疗高风险滤泡性淋巴瘤（FL）的应答情况
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
讲者：Reid Merryman, MD | Dana-Farber Cancer Institute
摘要号：7507
Brexucabtagene autoleucel（brexu - cel）治疗R/R套细胞淋巴瘤（MCL）的真实世界结局：一项CIBMTR亚组分析（不同既往治疗情况下）
Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.
讲者：Swetha Kambhampati, MD | City of Hope National Medical Center
摘要号：7508
利妥昔单抗维持治疗年轻套细胞淋巴瘤（MCL）患者的长期随访（包含于LYMA试验中）：一项LYSA研究
Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.
讲者：Steven Le Gouill, MD PhD | Institut Curie
本文依照报告日期和出场排序整理，如有错误或遗漏，敬请留言指正。
资料来源：
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/scheduled-sessions
排版编辑：Luna
苏公网安备 32059002004080号
